DUBLIN – Shares in Innocoll Holdings plc surged by more than 86 percent during pre-market trading on Nasdaq Wednesday on news of a takeover offer from Gurnet Point LP valued at up to $209 million. Read More
WASHINGTON – “Hallmarks and enabling characteristics should be not special cases, but rather reasonably broad across the spectrum of human cancers,” Robert Weinberg told BioWorld Today. Read More
Intezyne Technologies Inc. should find itself “on an IPO trajectory for late 2018 or early 2019,” its chief financial officer (CFO), Russell McAllister, told BioWorld Today, “coinciding with potential licensing deals for both” lead candidates owned by the Tampa, Fla.-based company. Read More
HONG KONG – The CFDA recently accepted a clinical trial application (CTA) to conduct phase I and phase III trials of rituximab biosimilar JHL1101, submitted by JHL Biotech Inc., a startup based in Zhubei City, Taiwan, and Wuhan, China. If successful, the biosimilar will be key to improving drug access in the country for patients with non-Hodgkin’s lymphoma (NHL). Read More
Ohr Pharmaceutical Inc., of New York, said it priced a registered public offering at 70 cents per share of common stock and accompanying warrant to purchase 0.7 of a share of common stock at an exercise price of $1 per share. Read More
Therapix Biosciences Ltd., of Tel Aviv, Israel, said Yissum Research Development Co. will grant it an exclusive, worldwide, sublicensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids. Read More
Bio-path Holdings Inc., of Houston, said its second product candidate, a neutral-charge, liposome-incorporated antisense drug called BP1002, was shown to have strong anti-non-Hodgkin’s lymphoma activity in preclinical in vitro and in vivo studies. Read More
Saniona AB, of Ballerup, Denmark, said it started a phase IIa study in the Czech Republic and Hungary for Tesomet in patients with Prader-Willi syndrome (PWS), having randomized the first three patients to either receive the drug, a combination of tesofensine 0.5 mg plus metoprolol 50 mg daily, or placebo. Read More
Reminding President Donald Trump of his promises to bring down drug prices, 51 members of Congress signed a letter to the president Tuesday urging him to direct the NIH to issue guidance on circumstances that could cause it to exercise its march-in rights on patents based on research it funded. Read More
Privately held Zavante Therapeutics Inc. hopes to push the antibiotics envelope a bit further after its single agent, Zolyd (fosfomycin for injection, previously ZTI-01), met the primary endpoint of statistical noninferiority to piperacillin/tazobactam (Zosyn, Pfizer Inc.) at the highest approved dose in the pivotal phase II/III ZEUS trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Read More
